darexaban glucuronide

**Darexaban glucuronide** is the **active metabolite** of darexaban, an oral direct Factor Xa (FXa) inhibitor developed primarily as an antithrombotic agent for prevention of venous thromboembolism and other thrombotic events. Following oral administration of darexaban, rapid and almost complete O-glucuronidation occurs, predominantly by the UDP-glucuronyltransferase (UGT) 1A family (especially UGT1A9 and UGT1A10), converting darexaban to darexaban glucuronide. Darexaban glucuronide is equipotent with darexaban as a direct, competitive inhibitor of factor Xa, suppressing prothrombin activation and thereby reducing blood clot formation. In vivo anti-FXa activity and antithrombotic effects are primarily mediated by darexaban glucuronide, which is responsible for the pharmacodynamic profile. It is excreted via urine and feces. Notably, darexaban glucuronide is not a substrate for CYP3A4 or P-glycoprotein and demonstrates a predictable pharmacokinetic/pharmacodynamic profile with minimal drug-drug interaction risks[1][2][3][4].

Other names

darexaban glucuronideYM-222714YM222714YM 222714